Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 15/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936093 | 0.85 | KLK7 (0.72) | KLK7 | |
| SCHEMBL19272546 | 0.84 | KLK7 (0.77) | KLK7TDP1ALDH1A1EPHX2 | |
| SCHEMBL16936037 | 0.83 | KLK7 (1.00) | KLK7TDP1ALDH1A1KMT2AEPHX2 | |
| SCHEMBL16936074 | 0.78 | KLK7 (1.00) | KLK7TDP1 | |
| SCHEMBL16936092 | 0.78 | KLK7 (1.00) | KLK7TDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL16936035 | 0.78 | KLK7 (1.00) | KLK7TDP1ALDH1A1KMT2A | |
| SCHEMBL22475175 | 0.77 | KLK7 (0.63) | KLK7TDP1 | |
| SCHEMBL16946225 | 0.76 | KLK7 (1.00) | KLK7ALDH1A1 | |
| SCHEMBL19272564 | 0.75 | KLK7 (0.60) | KLK7MEN1ALDH1A1KMT2AEPHX2 | |
| SCHEMBL16946201 | 0.75 | KLK7 (1.00) | KLK7TDP1MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | claimed |
| EP-3097084-B1 | NEW KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2020-09-30 | — | — | EP | disclosed |
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | disclosed |
| US-9744148-B2 | Kallikrein 7 inhibitors | SIXERA PHARMA AB (SE) | 2017-08-29 | — | — | US | disclosed |
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | SIXERA PHARMA AB (SE) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000753-A1 | KALLIKREIN 7 INHIBITORS | KLK7, KLK5, KLK1 | KLK7 1/4885TDP1 1785/4885MEN1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.